TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
Official title: Effectiveness of an Internet-based, Self-help, Asynchronized Behavioral Therapy With Mindfulness Approach for Adults With Tobacco Smoking or Vaping to Support Adults in Reducing Tobacco Smoking and Vaping in Switzerland and Türkiye
Run by University of Zurich · NCT07568483 · Data updated 2026-11-12
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 406 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Locations | 1 site (Zurich) |
| Status | Recruiting |
| Started | November 15, 2025 |
| Main results expected | June 30, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07568483 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18+ who currently smoke or vape (smoked on ≥1 day in the past 30 days or ≥100 lifetime cigarettes), have stable internet access, read German, English, or Turkish, and agree to randomization and follow-up assessments are ideal candidates.
✕Probably not a fit
People who prefer in-person medical care, require supervised pharmacotherapy or intensive cessation treatment, lack internet access or language proficiency, or are unwilling to be randomized may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
TUBSIS 2.0 is a fully remote, culturally adapted digital intervention that delivers eight structured modules over four weeks, integrating Health Action Process Approach principles with mindfulness and self-compassion exercises. Eligible adults are randomized to immediate access or a waitlist control and complete brief assessments at baseline, mid-intervention, post-intervention, and an eight-week follow-up. Primary outcomes include stage of behavior change, tobacco consumption patterns, and point-prevalence abstinence, with secondary outcomes such as mental well-being and nicotine dependence. The platform is anonymous, low-burden, and available in German, English, and Turkish.
Why it matters
Potential benefit: If successful, the program could increase quit or reduction rates and improve mental well-being while providing low-cost, anonymous support to people who face barriers to in-person services.
How similar studies have gone: Prior web-based and mindfulness-informed smoking cessation programs have shown modest success at increasing quit rates and well-being, but the multilingual, culturally adapted HAPA-plus-mindfulness combination and focus on vaping is less widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18 years or older * Smoking status: Smoked on ≥1 day in the past 30 days, and/or Smoked at least 100 cigarettes in lifetime * Internet access: Stable internet connection and access to a smartphone, tablet, or computer during interaction of the TUBSIS 2.0 web-based platform. * Language: Sufficient reading and listening comprehension in the study language (German, English or Turkish) * Contact: Valid email address and phone number (optional) for study communication, reminders and incentive payments * Consent: Provided electronic informed consent on TUBSIS 2.0 web-based platform which is developed and administrated by ISGF. * Study procedures: Agreement to randomization (intervention or control) and completion of study assessments at four time points (baseline, mid-intervention, post-intervention and 8-week follow-up) Exclusion Criteria: * Individuals who do not meet the inclusion criteria are excluded.
Where it's running
-
The Swiss Research Institute for Public Health and Addiction - ISGF (Schweizer Institut für Sucht- und Gesundheitsforschung)
Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Michael Schaub, Prof. Dr. phil. — Swiss Research Institute for Public Health and Addiction - ISGF, University of Zurich
- Study coordinator: Michael Schaub, Prof. Dr. phil.
- Email: michael.schaub@isgf.uzh.ch
- Phone: +41444481160
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
Ear acupressure plus nicotine replacement to ease withdrawal in psychiatric inpatients
This study will test whether adding ear acupressure (ear seeds) to standard nicotine replacement therapy helps psychiatric inpatients who must stop smoking reduce withdrawal symptoms, cravings, and anxiety.
-
Varenicline plus enhanced TMS to help adults quit smoking and vaping
This study tests whether adding active enhanced accelerated transcranial magnetic stimulation (aTMS) to varenicline helps adults 18–65 quit nicotine use more effectively than varenicline with sham stimulation.
-
Varenicline to help adults stop vaping
This trial tests whether the smoking-cessation pill varenicline helps adults who vape daily quit e-cigarettes.
-
tDCS plus varenicline to help people quit smoking
This will test if adding noninvasive tDCS brain stimulation to varenicline helps adults who smoke at least 8 cigarettes a day quit and stay smoke-free.
-
QuitVaping behavioral program with texting support to help teens stop vaping
This trial will try QuitVaping plus extra texting to see if it helps teens aged 14–18 who vape nicotine quit more than standard education and referral alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.